Brought to you by 
Arteaus Therapeutics takes on Lilly’s migraine compound; Lilly later regains rights
29 Apr 2020
Executive Summary
Specialty pharma start-up Arteaus Therapeutics LLC has licensed worldwide rights to develop one of Eli Lilly & Co.’s early-stage migraine prevention compounds.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arteaus Therapeutics takes on Lilly’s migraine compound; Lilly later regains rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice